Organization: Health Canada
Year: 2021
Month: January
Request Number: A-2020-000868
Request Summary: Adverse Reaction Report (AER) for C1 Esterase Inhibitor (Human). Report number: E2B_03184173. ADRs for GAMMAGARD LIQUID: 000914469, E2B_03202144. ADRs for Mesalazine: E2B_03203957, E2B_03208437. ADRs for VYVANSE: E2B_03174445, E2B_03175996, E2B_03222251.
Disposition: Disclosed in part
Number of pages: 116